Xcout IntelAmylyx Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Amylyx Pharmaceuticals, Inc. among biotechnology companies — ranked by similarity to what Amylyx Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Amylyx Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. at a glance
Amylyx Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, United States, founded in 2013. It is publicly listed (AMLX) with a market capitalisation of $3.1B. Xcout tracks 26 named people at Amylyx Pharmaceuticals, Inc., including Justin Klee (Co-CEO & Director). Xcout recorded 145 job postings from Amylyx Pharmaceuticals, Inc. in the last 90 days, naming tools such as NetSuite, Power BI.
Amylyx Pharmaceuticals, Inc. leadership
- Justin KleeCo-CEO & Director
- James FratesChief Financial Officer
- James M FratesChief Financial Officer
- Camille L BedrosianChief Medical Officer
- Gina MazzarielloChief Legal Officer & General Counsel
- Dan MonahanChief Commercial Officer
20 more named people on record for Amylyx Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Amylyx Pharmaceuticals, Inc. funding rounds on record
The most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt | $1.8M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Amylyx Pharmaceuticals, Inc.
Xcout recorded 145 job postings from Amylyx Pharmaceuticals, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Amylyx Pharmaceuticals, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Amylyx Pharmaceuticals, Inc.'s hiring signals →
Top 12 Amylyx Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Amylyx Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Similar biotechnology company
ProJenX, Inc. is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City. The firm focuses on neuroscience, developing novel, brain-penetrant therapies targeting biologically defined motor neuron diseases such as ALS. It advances research programs aimed at addressing severe neurodegenerative conditions.
Life Sciences
Libra Therapeutics is a biopharmaceutical company headquartered in Del Mar, California, focused on developing novel disease-modifying therapeutics. The company aims to restore cellular balance and improve lysosomal function to halt neurodegeneration in conditions such as amyotrophic lateral sclerosis.
Biotech
Prilenia Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative and neurodevelopmental disorders. Its lead drug candidate, pridopidine, has been studied in Huntington’s disease and amyotrophic lateral sclerosis (ALS), serving patients with serious neurological conditions.
Biotech
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Life Sciences
AZTherapies, Inc. is a private, late-stage clinical biopharmaceutical company founded in 2011 and headquartered in Boston, Massachusetts. The company focuses on developing novel treatments for devastating neurological conditions.
Biotech
LeonaBio, Inc. operates as a biopharmaceutical firm engaged in clinical-stage development. Its core mission revolves around crafting small molecule therapies aimed at revitalizing neurological function and arresting the advancement of neurodegenerative conditions. The company's active development portfolio encompasses ATH-1105, an experimental therapy for amyotrophic lateral sclerosis (ALS) that is currently undergoing Phase 1 clinical assessment. Similarly, ATH-1020 is also in Phase 1 trials, targeting various neurodegenerative disorders. Furthermore, LeonaBio has an array of earlier-stage compounds in preclinical research. The company, which was originally established as Athira Pharma, Inc., rebranded itself as LeonaBio, Inc. in January 2026. Founded in 2011, its corporate headquarters are situated in Bothell, Washington.
Similar biotechnology company
Axonis Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on discovering and developing novel treatments for neurological conditions and spinal cord injuries. Founded in 2019, the company advances therapeutic candidates through its proprietary research platform.
Biotech
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
Similar biotechnology company
Crucible Therapeutics is a biopharmaceutical company founded in 2023 to develop novel therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, originating from research at the Sheffield Institute for Translational Neuroscience.
Biotech
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Similar biotechnology company
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Amylyx Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Amylyx Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →